We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 47.95
Bid: 48.15
Ask: 49.30
Change: 0.00 (0.00%)
Spread: 1.15 (2.388%)
Open: 47.95
High: 47.95
Low: 47.95
Prev. Close: 47.95
IPO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Pre-closed-period update

13 Jan 2022 07:00

RNS Number : 2824Y
IP Group PLC
13 January 2022
 

FOR RELEASE ON

13 January 2022

 

IP Group plc - pre-closed-period update

 

Highlights

· FY21 profit anticipated to be above £425m (FY20: profit £185.4m)

· FY21 Hard NAV per share* anticipated to be above 165p (FY20: 125.3p), a return of at least 31%

· Net cash and deposits of £276m at 31 Dec 2021 (FY20: £203m)

· Portfolio companies well-funded having raised over £2bn in 2021 (FY20: £1.1bn)

 

IP Group plc (LSE: IPO) ("IP Group", "the Company" or "the Group"), the developer of intellectual property-based businesses, issues an unaudited pre-close update ahead of its results for the 12 months to 31 December 2021.

 

In financial terms, 2021 was another highly successful year with a large number of significant transactions including the flotation of Oxford Nanopore Technologies plc on the London Stock Exchange and the sales of Inivata Ltd and WaveOptics Ltd.

 

Consequently, the Directors currently expect the Group's profit for 2021 to be above £425m (FY20: profit £185.4m). Hard NAV per share is anticipated to be above 165 pence, a return of at least 31%.

 

The Group is in a strong financial position with net cash and deposits of £276m at year-end. The Group's portfolio is well funded with portfolio companies having raised over £2bn in 2021 (FY20: £1.1bn). This, combined with the exciting prospects and investment opportunities within the portfolio, gives us confidence for 2022.

 

IP Group expects to announce its 2021 results in mid-March.

 

Notes

 

*'Hard NAV per share' reflects net assets/total equity less goodwill and intangibles divided by outstanding shares.

 

The share price of Oxford Nanopore Technologies plc was 697 pence at 31 December 2021.

 

This update is based on unaudited information and is subject to change following the completion of the Group's usual full year-end reporting process and annual audit.

 

This announcement may contain forward looking statements. These statements reflect the Board's current view, are subject to a number of material risks and uncertainties and could change in the future. Factors which could cause or contribute to such changes include, but are not limited to, the general economic climate and market conditions, as well as specific factors relating to the financial or commercial prospects or performance of individual companies within the Group's portfolio.

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

David Baynes, Chief Financial and Operating OfficerLiz Vaughan-Adams, Communications

+44 (0) 20 7444 0050+44 (0) 20 7444 0062/+44 (0) 7979 853802

Charlotte Street Partners

David Gaffney

+44 (0) 7854 609998

Andrew Wilson

+44 (0) 7810 636995

 

Notes for editors

 

About IP Group

 

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

Group holdings in portfolio companies reflect the undiluted beneficial equity interest excluding debt, unless otherwise explicitly stated.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDBGDBCSBDGDD
Date   Source Headline
19th Sep 20189:51 amRNSDirector/PDMR Shareholding
17th Sep 20184:58 pmRNSDirector/PDMR Shareholding
17th Sep 20184:38 pmRNSDirector/PDMR Shareholding
17th Sep 201812:12 pmRNSDirector/PDMR Shareholding
17th Sep 20187:00 amRNSAppointment of Chairman; Board changes
31st Aug 20189:55 amRNSHolding(s) in Company
30th Aug 20187:00 amRNSGenomics announces Vertex leads £25m financing
29th Aug 20186:29 pmRNSIP Group plc -SAYE scheme
21st Aug 20187:06 amRNSCeres signs agreement with Bosch; £9m investment
10th Aug 20187:11 amRNSArtios Pharma completes £65m financing
31st Jul 20188:40 amRNSTR-1: NOTIFICATION
25th Jul 20187:00 amRNSHalf-yearly results
6th Jul 20187:00 amRNSNotification of Major Interest in Shares
4th Jul 20182:40 pmRNSCeres Power announces £20m fundraising
2nd Jul 20187:00 amRNSHolding(s) in Company
27th Jun 20187:30 amRNSCarisma announces $53m Series A funding round
27th Jun 20187:00 amRNSNotification of Major Interest in Shares
22nd Jun 201810:00 amRNSAppointment of Joint Broker
18th Jun 20181:37 pmRNSResult of AGM
7th Jun 20186:00 pmRNSHolding(s) in Company
6th Jun 20189:26 amRNSMicrobiotica signs collaboration worth up to $534m
16th May 201810:49 amRNSPortfolio co Ceres partners with Weichai Power
16th May 20187:00 amRNSNotice of AGM; Annual Report
11th May 20187:00 amRNSDirector/PDMR Shareholding
10th May 20186:18 pmRNSDirector/PDMR Shareholding
9th May 20185:31 pmRNSDirector share purchase
4th May 20187:00 amRNSBoard changes
30th Apr 20187:00 amRNSTotal Voting Rights
16th Apr 20185:45 pmRNSDirector/PDMR Shareholding
12th Apr 20189:19 amRNSEnterprise Therapeutics raises £29m
5th Apr 20181:12 pmRNSIP Group plc - Issue of Equity
4th Apr 201811:46 amRNSIP Group plc - Director/PDMR share purchase
29th Mar 20187:00 amRNSFinal Results
20th Mar 20187:00 amRNSOxford Nanopore announces £100m fundraising
17th Jan 201811:53 amRNSHolding(s) in Company
10th Jan 20189:12 amRNSHolding(s) in Company
2nd Jan 20187:00 amRNSTotal Voting Rights
18th Dec 201710:15 amRNSAutifony signs Eur627.5m agreement with BI
15th Dec 201712:50 pmRNSDiurnal receives positive CHMP opinion for Alkindi
14th Dec 20174:48 pmRNSDirectorate Change
13th Dec 20172:27 pmRNSIssue of Equity
8th Dec 20177:05 amRNSMirriad raises £26.2m; proposed admission to AIM
6th Dec 20172:32 pmRNSIssue of Equity
30th Nov 201712:40 pmRNSTotal Voting Rights
27th Nov 20176:27 pmRNSIssue of Equity
22nd Nov 20175:50 pmRNSHolding(s) in Company
22nd Nov 20173:23 pmRNSIssue of Equity
15th Nov 201712:47 pmRNSIssue of Equity
14th Nov 201712:29 pmRNSHolding(s) in Company
13th Nov 20177:00 amRNSNotice of cancellation of admission to AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.